---
layout: default
title: Paclitaxel
description: "Paclitaxel 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 122
evidence_level: L1
indication_count: 10
---

# Paclitaxel

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Paclitaxel 藥師筆記

## 一句話總結

<p class="key-answer" data-question="Paclitaxel 可以用於治療什麼新適應症？">
Paclitaxel 為紫杉醇類抗腫瘤藥物，TxGNN 預測其對乳癌 (包括三陰性乳癌、雌激素受體陽性乳癌) 有治療潛力，此預測已獲大量 Phase III 臨床試驗證實，證據等級最高。
</p>


---

## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥品名稱 | Paclitaxel (紫杉醇) |
| DrugBank ID | DB01229 |
| 台灣商品名 | 曲斯若凍晶注射劑、汰癌勝注射劑等 |
| 原適應症 | 卵巢癌、乳癌、非小細胞肺癌、胃癌、食道癌、頭頸癌、膀胱癌、子宮頸癌 |
| 預測新適應症 | 女性乳腺癌、hereditary breast ovarian cancer syndrome、estrogen-receptor negative breast cancer、hormone-resistant breast carcinoma、estrogen-receptor positive breast cancer、Ehrlich tumor carcinoma、bilateral breast carcinoma、breast carcinoma by gene expression profile、nipple carcinoma、ovarian clear cell adenocarcinoma |
| 證據等級 | L1 (多個 RCT) |
| TxGNN 預測分數 | 0.999+ |

---





## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>### 機轉連結</p>

<ol>
<li><strong>微管穩定作用</strong>：Paclitaxel 結合 beta-tubulin 促進微管聚合並穩定微管，抑制有絲分裂，導致細胞凋亡。</li>

<li><strong>免疫調節作用</strong>：最新研究顯示 paclitaxel 可調節腫瘤相關巨噬細胞 (TAM)，增強 PD-1 阻斷劑的療效。</li>

<li><strong>克服荷爾蒙抗性</strong>：對於荷爾蒙治療無效的 ER+ 乳癌，化療仍是重要選項，paclitaxel 透過不依賴荷爾蒙受體的機制發揮作用。</li>
</ol>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05244993" target="_blank">NCT05244993</a></td><td>PHASE2</td><td>UNKNOWN</td><td>42</td><td>AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-l...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07307911" target="_blank">NCT07307911</a></td><td>PHASE2</td><td>RECRUITING</td><td>50</td><td>Neuroprotective Effects of Coenzyme Q10 in Paclitaxel-Induced Peripheral Neuropa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03329950" target="_blank">NCT03329950</a></td><td>PHASE1</td><td>COMPLETED</td><td>132</td><td>A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Ad...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05107674" target="_blank">NCT05107674</a></td><td>PHASE1</td><td>RECRUITING</td><td>345</td><td>A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06636591" target="_blank">NCT06636591</a></td><td>NA</td><td>RECRUITING</td><td>14</td><td>A Prospective, Open-label, Single-center, Pilot Study of Neoadjuvant Chemotherap...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00404404" target="_blank">NCT00404404</a></td><td>PHASE2</td><td>UNKNOWN</td><td>35</td><td>Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05566457" target="_blank">NCT05566457</a></td><td>PHASE2</td><td>UNKNOWN</td><td>92</td><td>Clinical Study of Huangshi Guizhi Wuwu Decoction in Improving the Paclitaxel-rel...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00054028" target="_blank">NCT00054028</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>31</td><td>A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00019019" target="_blank">NCT00019019</a></td><td>PHASE1</td><td>COMPLETED</td><td>70</td><td>A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05809895" target="_blank">NCT05809895</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Eva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05207709" target="_blank">NCT05207709</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>456</td><td>A Phase III, Multicenter, Open-label Study of Ribociclib vs. Palbociclib in Pati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00589238" target="_blank">NCT00589238</a></td><td>PHASE2</td><td>TERMINATED</td><td>16</td><td>Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Comp...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03022162" target="_blank">NCT03022162</a></td><td>N/A</td><td>COMPLETED</td><td>150</td><td>Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02549534" target="_blank">NCT02549534</a></td><td>N/A</td><td>COMPLETED</td><td>29</td><td>Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00561119" target="_blank">NCT00561119</a></td><td>PHASE3</td><td>COMPLETED</td><td>326</td><td>Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00472693" target="_blank">NCT00472693</a></td><td>PHASE2</td><td>COMPLETED</td><td>5</td><td>A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01147016" target="_blank">NCT01147016</a></td><td>PHASE2</td><td>TERMINATED</td><td>8</td><td>A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00544167" target="_blank">NCT00544167</a></td><td>NA</td><td>COMPLETED</td><td>45</td><td>A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03799679" target="_blank">NCT03799679</a></td><td>PHASE4</td><td>UNKNOWN</td><td>60</td><td>Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00006459" target="_blank">NCT00006459</a></td><td>PHASE3</td><td>COMPLETED</td><td>N/A</td><td>Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients Wit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03644342" target="_blank">NCT03644342</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>4</td><td>Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Inva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00934895" target="_blank">NCT00934895</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>27</td><td>Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02954055" target="_blank">NCT02954055</a></td><td>PHASE2</td><td>COMPLETED</td><td>140</td><td>A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00001383" target="_blank">NCT00001383</a></td><td>PHASE1</td><td>COMPLETED</td><td>52</td><td>A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00513292" target="_blank">NCT00513292</a></td><td>PHASE3</td><td>COMPLETED</td><td>280</td><td>A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04126525" target="_blank">NCT04126525</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>53</td><td>NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-posi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01881230" target="_blank">NCT01881230</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>191</td><td>A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00281658" target="_blank">NCT00281658</a></td><td>PHASE3</td><td>COMPLETED</td><td>444</td><td>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00542451" target="_blank">NCT00542451</a></td><td>PHASE2</td><td>COMPLETED</td><td>406</td><td>A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00587925" target="_blank">NCT00587925</a></td><td>NA</td><td>COMPLETED</td><td>7</td><td>A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment fo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02125019" target="_blank">NCT02125019</a></td><td>N/A</td><td>COMPLETED</td><td>62</td><td>Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cance...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00499291" target="_blank">NCT00499291</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Na...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00272987" target="_blank">NCT00272987</a></td><td>PHASE3</td><td>TERMINATED</td><td>63</td><td>A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Com...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02071862" target="_blank">NCT02071862</a></td><td>PHASE1</td><td>COMPLETED</td><td>210</td><td>Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06176339" target="_blank">NCT06176339</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>70</td><td>&quot;Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemothe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01454479" target="_blank">NCT01454479</a></td><td>PHASE1</td><td>UNKNOWN</td><td>24</td><td>A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Tre...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00311636" target="_blank">NCT00311636</a></td><td>PHASE3</td><td>COMPLETED</td><td>280</td><td>Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04644068" target="_blank">NCT04644068</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>702</td><td>A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Toler...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00954174" target="_blank">NCT00954174</a></td><td>PHASE3</td><td>UNKNOWN</td><td>637</td><td>A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725059" target="_blank">NCT03725059</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>1240</td><td>A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01583426" target="_blank">NCT01583426</a></td><td>PHASE3</td><td>COMPLETED</td><td>1229</td><td>A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solven...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07074106" target="_blank">NCT07074106</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>40</td><td>DespaTIL Study: A Phase II Trial of De-escalated Neoadjuvant Chemotherapy for Ea...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01094184" target="_blank">NCT01094184</a></td><td>PHASE4</td><td>COMPLETED</td><td>49</td><td>Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07103447" target="_blank">NCT07103447</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>54</td><td>A Prospective, Multicenter, Single-Arm Study of AK112 in Combination With Albumi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02225652" target="_blank">NCT02225652</a></td><td>PHASE2</td><td>COMPLETED</td><td>11</td><td>A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00262847" target="_blank">NCT00262847</a></td><td>PHASE3</td><td>COMPLETED</td><td>1873</td><td>A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04677816" target="_blank">NCT04677816</a></td><td>PHASE2</td><td>RECRUITING</td><td>50</td><td>Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05143970" target="_blank">NCT05143970</a></td><td>PHASE1</td><td>RECRUITING</td><td>27</td><td>A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01405924" target="_blank">NCT01405924</a></td><td>PHASE2</td><td>TERMINATED</td><td>111</td><td>EMEND® IV In Salvage Treatment of Chemotherapy-Induced Vomiting</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03601897" target="_blank">NCT03601897</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>177</td><td>An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combina...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31783552/" target="_blank">31783552</a></td><td>2019</td><td>Article</td><td>Biomolecules</td><td>Paclitaxel&#x27;s Mechanistic and Clinical Effects on Breast Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39009452/" target="_blank">39009452</a></td><td>2024</td><td>Article</td><td>Journal for immunotherapy of c</td><td>Novel insights into paclitaxel&#x27;s role on tumor-associated macrophages in enhanci...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9282422/" target="_blank">9282422</a></td><td>1997</td><td>Article</td><td>Drug and therapeutics bulletin</td><td>Paclitaxel and docetaxel in breast and ovarian cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24823476/" target="_blank">24823476</a></td><td>2014</td><td>Article</td><td>Nature communications</td><td>Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31515668/" target="_blank">31515668</a></td><td>2019</td><td>Article</td><td>Cancer chemotherapy and pharma</td><td>Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28126294/" target="_blank">28126294</a></td><td>2017</td><td>Article</td><td>International journal of radia</td><td>Internal Mammary Misfortune.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11147586/" target="_blank">11147586</a></td><td>2000</td><td>Article</td><td>Cancer</td><td>Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adj...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39317691/" target="_blank">39317691</a></td><td>2024</td><td>Article</td><td>Chemical biology &amp; drug design</td><td>Unveiling the Therapeutic Potential of Paclitaxel Combinations Against Breast Ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36964413/" target="_blank">36964413</a></td><td>2023</td><td>Article</td><td>Human cell</td><td>TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36221929/" target="_blank">36221929</a></td><td>2023</td><td>Article</td><td>Journal of biomedical material</td><td>Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxici...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10928395/" target="_blank">10928395</a></td><td>2000</td><td>Article</td><td>The Annals of pharmacotherapy</td><td>Cyclosporine-induced anaphylaxis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20665703/" target="_blank">20665703</a></td><td>2011</td><td>Article</td><td>Journal of cellular physiology</td><td>ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast car...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11745249/" target="_blank">11745249</a></td><td>2001</td><td>Article</td><td>Cancer</td><td>Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32461977/" target="_blank">32461977</a></td><td>2020</td><td>Article</td><td>BioMed research international</td><td>Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and We...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10791395/" target="_blank">10791395</a></td><td>2000</td><td>Article</td><td>Lancet (London, England)</td><td>The taxanes: an update.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22353935/" target="_blank">22353935</a></td><td>2012</td><td>Article</td><td>Cancer biology &amp; therapy</td><td>Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39400682/" target="_blank">39400682</a></td><td>2024</td><td>Article</td><td>Medical oncology (Northwood, L</td><td>Glycolytic pathway analysis and gene expression profiles of combination of aloe ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39471010/" target="_blank">39471010</a></td><td>2024</td><td>Article</td><td>Asian Pacific journal of cance</td><td>Molecular Docking and Pharmacokinetic Profiling of Nab-paclitaxel as Advanced Ch...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10517345/" target="_blank">10517345</a></td><td>1999</td><td>Article</td><td>Breast cancer research and tre</td><td>Schedule-dependent interactions between vinorelbine and paclitaxel in human carc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16435143/" target="_blank">16435143</a></td><td>2006</td><td>Article</td><td>Journal of cancer research and</td><td>Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy f...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. estrogen-receptor negative breast cancer</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（50 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01777932" target="_blank">NCT01777932</a></td><td>N/A</td><td>COMPLETED</td><td>220</td><td>A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04132817" target="_blank">NCT04132817</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02734290" target="_blank">NCT02734290</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>29</td><td>A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04152057" target="_blank">NCT04152057</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>20</td><td>A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01897441" target="_blank">NCT01897441</a></td><td>NA</td><td>TERMINATED</td><td>31</td><td>Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01147016" target="_blank">NCT01147016</a></td><td>PHASE2</td><td>TERMINATED</td><td>8</td><td>A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725436" target="_blank">NCT03725436</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>35</td><td>A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01565499" target="_blank">NCT01565499</a></td><td>PHASE2</td><td>COMPLETED</td><td>83</td><td>Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02954055" target="_blank">NCT02954055</a></td><td>PHASE2</td><td>COMPLETED</td><td>140</td><td>A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01816594" target="_blank">NCT01816594</a></td><td>PHASE2</td><td>COMPLETED</td><td>50</td><td>NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Ran...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04770272" target="_blank">NCT04770272</a></td><td>PHASE2</td><td>TERMINATED</td><td>442</td><td>An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cance...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01881230" target="_blank">NCT01881230</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>191</td><td>A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxe...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01421472" target="_blank">NCT01421472</a></td><td>PHASE2</td><td>COMPLETED</td><td>196</td><td>A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04247126" target="_blank">NCT04247126</a></td><td>PHASE1</td><td>COMPLETED</td><td>105</td><td>A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00773695" target="_blank">NCT00773695</a></td><td>PHASE2</td><td>COMPLETED</td><td>150</td><td>A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Ava...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05325632" target="_blank">NCT05325632</a></td><td>PHASE2</td><td>RECRUITING</td><td>53</td><td>A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed De...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02598310" target="_blank">NCT02598310</a></td><td>PHASE2</td><td>TERMINATED</td><td>30</td><td>Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00003440" target="_blank">NCT00003440</a></td><td>PHASE3</td><td>COMPLETED</td><td>580</td><td>A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hou...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725059" target="_blank">NCT03725059</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>1240</td><td>A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03554109" target="_blank">NCT03554109</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative B...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01818063" target="_blank">NCT01818063</a></td><td>PHASE2</td><td>COMPLETED</td><td>9</td><td>An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04243616" target="_blank">NCT04243616</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>36</td><td>Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01094184" target="_blank">NCT01094184</a></td><td>PHASE4</td><td>COMPLETED</td><td>49</td><td>Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00070564" target="_blank">NCT00070564</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>3294</td><td>Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06746870" target="_blank">NCT06746870</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>148</td><td>A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02685306" target="_blank">NCT02685306</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase II Study to Determine the Pathological Complete Response Rate and Immuno...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04443348" target="_blank">NCT04443348</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>120</td><td>P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Lo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02530489" target="_blank">NCT02530489</a></td><td>PHASE2</td><td>COMPLETED</td><td>37</td><td>Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL32...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01303679" target="_blank">NCT01303679</a></td><td>PHASE3</td><td>TERMINATED</td><td>117</td><td>Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03726879" target="_blank">NCT03726879</a></td><td>PHASE3</td><td>COMPLETED</td><td>454</td><td>A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Eval...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06656624" target="_blank">NCT06656624</a></td><td>PHASE2</td><td>RECRUITING</td><td>190</td><td>Efficacy and Safety of Ribociclib Combined With AI Versus Physician&amp;Amp;#39;s Ch...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02483767" target="_blank">NCT02483767</a></td><td>PHASE3</td><td>COMPLETED</td><td>98</td><td>Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06964906" target="_blank">NCT06964906</a></td><td>PHASE2</td><td>RECRUITING</td><td>140</td><td>A Randomized, Open-Label, Blinded Endpoint Study of High-Intensity Focused Ultra...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05302336" target="_blank">NCT05302336</a></td><td>PHASE4</td><td>UNKNOWN</td><td>402</td><td>A Randomized Controlled Study of AC (Doxorubicin Hydrochloride Liposome/Cyclopho...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05594095" target="_blank">NCT05594095</a></td><td>PHASE2</td><td>RECRUITING</td><td>620</td><td>Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04602117" target="_blank">NCT04602117</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01307891" target="_blank">NCT01307891</a></td><td>PHASE2</td><td>COMPLETED</td><td>64</td><td>An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00542191" target="_blank">NCT00542191</a></td><td>PHASE2</td><td>TERMINATED</td><td>30</td><td>Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01276496" target="_blank">NCT01276496</a></td><td>PHASE1</td><td>COMPLETED</td><td>13</td><td>A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pha...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01698281" target="_blank">NCT01698281</a></td><td>PHASE2</td><td>TERMINATED</td><td>7</td><td>A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negativ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00856492" target="_blank">NCT00856492</a></td><td>PHASE2</td><td>COMPLETED</td><td>215</td><td>A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03841747" target="_blank">NCT03841747</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Pacl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00667251" target="_blank">NCT00667251</a></td><td>PHASE3</td><td>COMPLETED</td><td>652</td><td>A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04745975" target="_blank">NCT04745975</a></td><td>PHASE2</td><td>UNKNOWN</td><td>100</td><td>GUided Treatment Based on Mini-PDX in metastaTIc refractOry Triple Negative Brea...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05981014" target="_blank">NCT05981014</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>196</td><td>An Open-Label Phase I/II Study of Autologous Tumor-Draining Lymph Node-Derived L...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03387085" target="_blank">NCT03387085</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>9</td><td>NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01625286" target="_blank">NCT01625286</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>148</td><td>A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06121570" target="_blank">NCT06121570</a></td><td>PHASE1</td><td>RECRUITING</td><td>24</td><td>Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01159236" target="_blank">NCT01159236</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02603679" target="_blank">NCT02603679</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>181</td><td>PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38771995/" target="_blank">38771995</a></td><td>2024</td><td>Article</td><td>Journal of clinical oncology :</td><td>Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combinat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33015734/" target="_blank">33015734</a></td><td>2021</td><td>Article</td><td>Cancer immunology, immunothera</td><td>Pembrolizumab and atezolizumab in triple-negative breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37440239/" target="_blank">37440239</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs W...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37526149/" target="_blank">37526149</a></td><td>2023</td><td>Article</td><td>Future oncology (London, Engla</td><td>TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or met...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39838117/" target="_blank">39838117</a></td><td>2025</td><td>Article</td><td>Nature medicine</td><td>Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cance...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39631485/" target="_blank">39631485</a></td><td>2024</td><td>Article</td><td>Pharmacological research</td><td>Targeted and cytotoxic inhibitors used in the treatment of breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24523301/" target="_blank">24523301</a></td><td>2014</td><td>Article</td><td>Molecular cancer therapeutics</td><td>Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31786121/" target="_blank">31786121</a></td><td>2020</td><td>Article</td><td>The Lancet. Oncology</td><td>Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, local...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28135148/" target="_blank">28135148</a></td><td>2017</td><td>Article</td><td>Journal of clinical oncology :</td><td>Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residua...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29604436/" target="_blank">29604436</a></td><td>2018</td><td>Article</td><td>Pharmacological research</td><td>Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40049198/" target="_blank">40049198</a></td><td>2025</td><td>Article</td><td>The Lancet. Oncology</td><td>Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36982940/" target="_blank">36982940</a></td><td>2023</td><td>Article</td><td>International journal of molec</td><td>Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem C...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36241702/" target="_blank">36241702</a></td><td>2023</td><td>Article</td><td>Cancer gene therapy</td><td>Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34911787/" target="_blank">34911787</a></td><td>2022</td><td>Article</td><td>Cancer research</td><td>Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15023242/" target="_blank">15023242</a></td><td>2004</td><td>Article</td><td>Clinical breast cancer</td><td>Paclitaxel improves the prognosis in estrogen receptor negative inflammatory bre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35795050/" target="_blank">35795050</a></td><td>2022</td><td>Article</td><td>Frontiers in oncology</td><td>Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30860570/" target="_blank">30860570</a></td><td>2019</td><td>Article</td><td>Annals of oncology : official </td><td>BEECH: a dose-finding run-in followed by a randomised phase II study assessing t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39644440/" target="_blank">39644440</a></td><td>2025</td><td>Article</td><td>Breast cancer (Tokyo, Japan)</td><td>Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for earl...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30802822/" target="_blank">30802822</a></td><td>2019</td><td>Article</td><td>Breast (Edinburgh, Scotland)</td><td>Randomized phase II study evaluating weekly oral vinorelbine versus weekly pacli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35976445/" target="_blank">35976445</a></td><td>2023</td><td>Article</td><td>Journal of cancer research and</td><td>Triple negative breast cancer: approved treatment options and their mechanisms o...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. hormone-resistant breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（14 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03285607" target="_blank">NCT03285607</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclop...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02616848" target="_blank">NCT02616848</a></td><td>PHASE1</td><td>UNKNOWN</td><td>1</td><td>Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-neg...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04771871" target="_blank">NCT04771871</a></td><td>PHASE2</td><td>UNKNOWN</td><td>42</td><td>Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patien...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02603679" target="_blank">NCT02603679</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>181</td><td>PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01031446" target="_blank">NCT01031446</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>55</td><td>A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metast...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04158362" target="_blank">NCT04158362</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>180</td><td>Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemoth...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07327021" target="_blank">NCT07327021</a></td><td>PHASE2</td><td>RECRUITING</td><td>54</td><td>NOGA: Neoadjuvant Treatment Optimization Via MRI-Guided De-Escalation in Stage I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03925233" target="_blank">NCT03925233</a></td><td>N/A</td><td>UNKNOWN</td><td>300</td><td>Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03179904" target="_blank">NCT03179904</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>19</td><td>Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Comb...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01779479" target="_blank">NCT01779479</a></td><td>PHASE2</td><td>COMPLETED</td><td>333</td><td>Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05429684" target="_blank">NCT05429684</a></td><td>PHASE3</td><td>UNKNOWN</td><td>120</td><td>Precise Targeted Therapy for Refractory HER2 Positive Advanced Breast Cancer Bas...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03358004" target="_blank">NCT03358004</a></td><td>PHASE2</td><td>TERMINATED</td><td>4</td><td>An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investig...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06734533" target="_blank">NCT06734533</a></td><td>N/A</td><td>RECRUITING</td><td>80</td><td>A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03444025" target="_blank">NCT03444025</a></td><td>PHASE2</td><td>UNKNOWN</td><td>180</td><td>Prospective Phase II Randomized Trial of Evaluating the Effect of Adding LHRH An...</td></tr>
</tbody>
</table>

<h3>相關文獻（9 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9071337/" target="_blank">9071337</a></td><td>1997</td><td>Article</td><td>Seminars in oncology</td><td>Response to estramustine phosphate and paclitaxel in patients with advanced brea...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8091238/" target="_blank">8091238</a></td><td>1994</td><td>Article</td><td>Seminars in oncology</td><td>Salvage chemotherapy of breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34781168/" target="_blank">34781168</a></td><td>2021</td><td>Article</td><td>European journal of cancer (Ox</td><td>TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7481851/" target="_blank">7481851</a></td><td>1995</td><td>Article</td><td>Seminars in oncology</td><td>Management of breast cancer: status and future trends.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9374083/" target="_blank">9374083</a></td><td>1997</td><td>Article</td><td>Seminars in oncology</td><td>Chemotherapy of breast cancer: a historical perspective.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12353824/" target="_blank">12353824</a></td><td>2002</td><td>Article</td><td>Breast cancer research and tre</td><td>The role of EGFR-directed therapy in the treatment of breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17475221/" target="_blank">17475221</a></td><td>2007</td><td>Article</td><td>Biochemical pharmacology</td><td>Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20462978/" target="_blank">20462978</a></td><td>2010</td><td>Article</td><td>Japanese journal of clinical o</td><td>Randomized study of taxane versus TS-1 in women with metastatic or recurrent bre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27306814/" target="_blank">27306814</a></td><td>2016</td><td>Article</td><td>Gan to kagaku ryoho. Cancer &amp; </td><td>[An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse E...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. estrogen-receptor positive breast cancer</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（50 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01777932" target="_blank">NCT01777932</a></td><td>N/A</td><td>COMPLETED</td><td>220</td><td>A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06202261" target="_blank">NCT06202261</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>154</td><td>A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of TQB2930 for ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04132817" target="_blank">NCT04132817</a></td><td>PHASE1</td><td>COMPLETED</td><td>12</td><td>A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04152057" target="_blank">NCT04152057</a></td><td>PHASE1, PHASE2</td><td>UNKNOWN</td><td>20</td><td>A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01897441" target="_blank">NCT01897441</a></td><td>NA</td><td>TERMINATED</td><td>31</td><td>Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01147016" target="_blank">NCT01147016</a></td><td>PHASE2</td><td>TERMINATED</td><td>8</td><td>A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725436" target="_blank">NCT03725436</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>35</td><td>A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01565499" target="_blank">NCT01565499</a></td><td>PHASE2</td><td>COMPLETED</td><td>83</td><td>Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02954055" target="_blank">NCT02954055</a></td><td>PHASE2</td><td>COMPLETED</td><td>140</td><td>A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01816594" target="_blank">NCT01816594</a></td><td>PHASE2</td><td>COMPLETED</td><td>50</td><td>NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Ran...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01421472" target="_blank">NCT01421472</a></td><td>PHASE2</td><td>COMPLETED</td><td>196</td><td>A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04247126" target="_blank">NCT04247126</a></td><td>PHASE1</td><td>COMPLETED</td><td>105</td><td>A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05325632" target="_blank">NCT05325632</a></td><td>PHASE2</td><td>RECRUITING</td><td>53</td><td>A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed De...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00407888" target="_blank">NCT00407888</a></td><td>PHASE2</td><td>COMPLETED</td><td>60</td><td>Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin +...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02598310" target="_blank">NCT02598310</a></td><td>PHASE2</td><td>TERMINATED</td><td>30</td><td>Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725059" target="_blank">NCT03725059</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>1240</td><td>A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04243616" target="_blank">NCT04243616</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>36</td><td>Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00070564" target="_blank">NCT00070564</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>3294</td><td>Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04443348" target="_blank">NCT04443348</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>120</td><td>P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Lo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01303679" target="_blank">NCT01303679</a></td><td>PHASE3</td><td>TERMINATED</td><td>117</td><td>Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03726879" target="_blank">NCT03726879</a></td><td>PHASE3</td><td>COMPLETED</td><td>454</td><td>A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Eval...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06964906" target="_blank">NCT06964906</a></td><td>PHASE2</td><td>RECRUITING</td><td>140</td><td>A Randomized, Open-Label, Blinded Endpoint Study of High-Intensity Focused Ultra...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05302336" target="_blank">NCT05302336</a></td><td>PHASE4</td><td>UNKNOWN</td><td>402</td><td>A Randomized Controlled Study of AC (Doxorubicin Hydrochloride Liposome/Cyclopho...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01491737" target="_blank">NCT01491737</a></td><td>PHASE2</td><td>COMPLETED</td><td>258</td><td>A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Effi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05594095" target="_blank">NCT05594095</a></td><td>PHASE2</td><td>RECRUITING</td><td>620</td><td>Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04602117" target="_blank">NCT04602117</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02654119" target="_blank">NCT02654119</a></td><td>PHASE2</td><td>COMPLETED</td><td>20</td><td>A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00856492" target="_blank">NCT00856492</a></td><td>PHASE2</td><td>COMPLETED</td><td>215</td><td>A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03841747" target="_blank">NCT03841747</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Pacl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00667251" target="_blank">NCT00667251</a></td><td>PHASE3</td><td>COMPLETED</td><td>652</td><td>A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01625286" target="_blank">NCT01625286</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>148</td><td>A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01159236" target="_blank">NCT01159236</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02603679" target="_blank">NCT02603679</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>181</td><td>PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07187674" target="_blank">NCT07187674</a></td><td>NA</td><td>NOT_YET_RECRUITING</td><td>20</td><td>Single Arm, Prospective, Small Sample, Exploratory Clinical Study on the Neoadju...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00785291" target="_blank">NCT00785291</a></td><td>PHASE3</td><td>COMPLETED</td><td>799</td><td>A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05296746" target="_blank">NCT05296746</a></td><td>PHASE2</td><td>RECRUITING</td><td>1100</td><td>Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-ri...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06474988" target="_blank">NCT06474988</a></td><td>N/A</td><td>RECRUITING</td><td>150</td><td>Characterization of Biophysical and Mechanical Parameters on the Skin of Subject...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00005970" target="_blank">NCT00005970</a></td><td>PHASE3</td><td>COMPLETED</td><td>3436</td><td>Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Pacl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00194792" target="_blank">NCT00194792</a></td><td>PHASE2</td><td>TERMINATED</td><td>28</td><td>Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00063999" target="_blank">NCT00063999</a></td><td>PHASE3</td><td>COMPLETED</td><td>1381</td><td>Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01830244" target="_blank">NCT01830244</a></td><td>PHASE2</td><td>UNKNOWN</td><td>60</td><td>Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Album...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05831553" target="_blank">NCT05831553</a></td><td>N/A</td><td>UNKNOWN</td><td>100</td><td>Evaluation of a Tissue Immune Profile (TIP) in Patients Affected by Metastatic T...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04038489" target="_blank">NCT04038489</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Ther...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06099769" target="_blank">NCT06099769</a></td><td>PHASE2</td><td>RECRUITING</td><td>201</td><td>A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, an...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02476955" target="_blank">NCT02476955</a></td><td>PHASE1</td><td>TERMINATED</td><td>41</td><td>An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06500208" target="_blank">NCT06500208</a></td><td>PHASE2</td><td>RECRUITING</td><td>48</td><td>An Open-label, One-arm Phase II Study of Adebrelimab Combined With Neoadjuvant C...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04753177" target="_blank">NCT04753177</a></td><td>PHASE2, PHASE3</td><td>UNKNOWN</td><td>120</td><td>The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Adv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02018458" target="_blank">NCT02018458</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>10</td><td>Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vac...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00003992" target="_blank">NCT00003992</a></td><td>PHASE2</td><td>COMPLETED</td><td>200</td><td>Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Canc...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00455533" target="_blank">NCT00455533</a></td><td>PHASE2</td><td>COMPLETED</td><td>384</td><td>A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by I...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38771995/" target="_blank">38771995</a></td><td>2024</td><td>Article</td><td>Journal of clinical oncology :</td><td>Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combinat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37440239/" target="_blank">37440239</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs W...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30413379/" target="_blank">30413379</a></td><td>2018</td><td>Article</td><td>The Lancet. Oncology</td><td>Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39838117/" target="_blank">39838117</a></td><td>2025</td><td>Article</td><td>Nature medicine</td><td>Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cance...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39631485/" target="_blank">39631485</a></td><td>2024</td><td>Article</td><td>Pharmacological research</td><td>Targeted and cytotoxic inhibitors used in the treatment of breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33015734/" target="_blank">33015734</a></td><td>2021</td><td>Article</td><td>Cancer immunology, immunothera</td><td>Pembrolizumab and atezolizumab in triple-negative breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34014249/" target="_blank">34014249</a></td><td>2021</td><td>Article</td><td>JAMA oncology</td><td>Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28135148/" target="_blank">28135148</a></td><td>2017</td><td>Article</td><td>Journal of clinical oncology :</td><td>Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residua...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29604436/" target="_blank">29604436</a></td><td>2018</td><td>Article</td><td>Pharmacological research</td><td>Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatm...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28945833/" target="_blank">28945833</a></td><td>2017</td><td>Article</td><td>Annals of oncology : official </td><td>De-escalation strategies in HER2-positive early breast cancer (EBC): final analy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31786121/" target="_blank">31786121</a></td><td>2020</td><td>Article</td><td>The Lancet. Oncology</td><td>Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, local...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40049198/" target="_blank">40049198</a></td><td>2025</td><td>Article</td><td>The Lancet. Oncology</td><td>Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36241702/" target="_blank">36241702</a></td><td>2023</td><td>Article</td><td>Cancer gene therapy</td><td>Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24523301/" target="_blank">24523301</a></td><td>2014</td><td>Article</td><td>Molecular cancer therapeutics</td><td>Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34911787/" target="_blank">34911787</a></td><td>2022</td><td>Article</td><td>Cancer research</td><td>Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41315271/" target="_blank">41315271</a></td><td>2025</td><td>Article</td><td>Nature communications</td><td>Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30860570/" target="_blank">30860570</a></td><td>2019</td><td>Article</td><td>Annals of oncology : official </td><td>BEECH: a dose-finding run-in followed by a randomised phase II study assessing t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30802822/" target="_blank">30802822</a></td><td>2019</td><td>Article</td><td>Breast (Edinburgh, Scotland)</td><td>Randomized phase II study evaluating weekly oral vinorelbine versus weekly pacli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32013102/" target="_blank">32013102</a></td><td>2020</td><td>Article</td><td>Cancers</td><td>Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profil...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37622644/" target="_blank">37622644</a></td><td>2023</td><td>Article</td><td>Danish medical journal</td><td>Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Ehrlich tumor carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（1 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04885270" target="_blank">NCT04885270</a></td><td>PHASE3</td><td>UNKNOWN</td><td>50</td><td>Phase III Clinical Trial of Intravenous Paclitaxel Plus Intraperitoneal Cisplati...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30342146/" target="_blank">30342146</a></td><td>2019</td><td>Article</td><td>International journal of biolo</td><td>Acylated chitosan anchored paclitaxel loaded liposomes: Pharmacokinetic and biod...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31002367/" target="_blank">31002367</a></td><td>2019</td><td>Article</td><td>Oncology reports</td><td>Dietary baker&#x27;s yeast sensitizes Ehrlich mammary adenocarcinoma to paclitaxel in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27426109/" target="_blank">27426109</a></td><td>2016</td><td>Article</td><td>International journal of pharm</td><td>Heparin modification enhances the delivery and tumor targeting of paclitaxel-loa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26500095/" target="_blank">26500095</a></td><td>2016</td><td>Article</td><td>Tumour biology : the journal o</td><td>The combination of thymoquinone and paclitaxel shows anti-tumor activity through...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17385543/" target="_blank">17385543</a></td><td>2007</td><td>Article</td><td>Acta biologica Hungarica</td><td>Evaluation of the effect of paclitaxel, epirubicin and tamoxifen by cell kinetic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26792072/" target="_blank">26792072</a></td><td>2016</td><td>Article</td><td>Radiation oncology (London, En</td><td>Second-line treatment of recurrent HNSCC: tumor debulking in combination with hi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28950656/" target="_blank">28950656</a></td><td>2017</td><td>Article</td><td>Biomedicine &amp; pharmacotherapy </td><td>Oxamate potentiates taxol chemotherapeutic efficacy in experimentally-induced so...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33338480/" target="_blank">33338480</a></td><td>2021</td><td>Article</td><td>Experimental cell research</td><td>Antineoplastic activity of Salmonella Typhimurium outer membrane nanovesicles.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26255673/" target="_blank">26255673</a></td><td>2016</td><td>Article</td><td>Anti-cancer agents in medicina</td><td>Paclitaxel Loaded Nanoliposomes in Thermosensitive Hydrogel: A Dual Approach for...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28063824/" target="_blank">28063824</a></td><td>2017</td><td>Article</td><td>Journal of pharmaceutical scie</td><td>Development of Safe and Potent Oil-in-Water Emulsion of Paclitaxel to Treat Peri...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35716981/" target="_blank">35716981</a></td><td>2022</td><td>Article</td><td>International journal of pharm</td><td>Effects of particle size and release property of paclitaxel-loaded nanoparticles...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27367621/" target="_blank">27367621</a></td><td>2016</td><td>Article</td><td>Nutrition and cancer</td><td>Enhancing the Apoptotic Effect of a Low Dose of Paclitaxel on Tumor Cells in Mic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24369111/" target="_blank">24369111</a></td><td>2014</td><td>Article</td><td>Current drug safety</td><td>Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free al...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22809646/" target="_blank">22809646</a></td><td>2012</td><td>Article</td><td>Biomaterials</td><td>Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31628941/" target="_blank">31628941</a></td><td>2020</td><td>Article</td><td>Chemico-biological interaction</td><td>Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug res...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26528585/" target="_blank">26528585</a></td><td>2015</td><td>Article</td><td>ACS applied materials &amp; interf</td><td>pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10731049/" target="_blank">10731049</a></td><td>2000</td><td>Article</td><td>Naunyn-Schmiedeberg&#x27;s archives</td><td>Differential alteration of cisplatin cytotoxicity and myelotoxicity by the pacli...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27381609/" target="_blank">27381609</a></td><td>2016</td><td>Article</td><td>In vivo (Athens, Greece)</td><td>Apoptosis-inducing Effect of a Palladium(II) Complex-[PdCl(terpy)](sac).2H2O] on...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25750302/" target="_blank">25750302</a></td><td>2015</td><td>Article</td><td>Anticancer research</td><td>Anticancer effect of a novel palladium-saccharinate complex of terpyridine by in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29161917/" target="_blank">29161917</a></td><td>2018</td><td>Article</td><td>Integrative cancer therapies</td><td>Baker&#x27;s Yeast Sensitizes Metastatic Breast Cancer Cells to Paclitaxel In Vitro.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. bilateral breast carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（5 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02364726" target="_blank">NCT02364726</a></td><td>NA</td><td>COMPLETED</td><td>28</td><td>Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04461977" target="_blank">NCT04461977</a></td><td>NA</td><td>COMPLETED</td><td>60</td><td>Acupuncture for Treatment of Peripheral Neuropathy Induced by Neoadjuvant or Adj...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02457039" target="_blank">NCT02457039</a></td><td>NA</td><td>COMPLETED</td><td>93</td><td>An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03873272" target="_blank">NCT03873272</a></td><td>NA</td><td>COMPLETED</td><td>63</td><td>Randomized Controlled Selection Trial of Cryotherapy vs. Compression Therapy for...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05861830" target="_blank">NCT05861830</a></td><td>PHASE3</td><td>RECRUITING</td><td>80</td><td>An Exploratory Study on Predicting the Efficacy of Dalpiciclib in Combination Wi...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40690248/" target="_blank">40690248</a></td><td>2025</td><td>Article</td><td>JAMA</td><td>Ovarian Cancer: A Review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36068624/" target="_blank">36068624</a></td><td>2022</td><td>Article</td><td>International journal of retin</td><td>Bilateral intermediate uveitis following treatment with paclitaxel in a patient ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36335424/" target="_blank">36335424</a></td><td>2022</td><td>Article</td><td>The American journal of case r</td><td>Gynecomastia and Malignancy: A Case of Male Invasive Ductal Breast Carcinoma Tre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25978147/" target="_blank">25978147</a></td><td>2017</td><td>Article</td><td>Journal of chemotherapy (Flore</td><td>Paclitaxel-induced pneumonitis in patients with breast cancer: case series and r...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11876386/" target="_blank">11876386</a></td><td>2002</td><td>Article</td><td>European journal of gynaecolog</td><td>Primary breast carcinoma of the vulva: case report and review of literature.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38741768/" target="_blank">38741768</a></td><td>2024</td><td>Article</td><td>Frontiers in medicine</td><td>Untypical bilateral breast cancer with peritoneal fibrosis on 18F-FDG PET/CT: ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38283858/" target="_blank">38283858</a></td><td>2024</td><td>Article</td><td>Frontiers in oncology</td><td>Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15507181/" target="_blank">15507181</a></td><td>2004</td><td>Article</td><td>Clinical breast cancer</td><td>Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41323054/" target="_blank">41323054</a></td><td>2025</td><td>Article</td><td>Case reports in oncology</td><td>Synchronous Bilateral Breast Cancer with Heterogeneous Histology: Invasive Ducta...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12603378/" target="_blank">12603378</a></td><td>2003</td><td>Article</td><td>The breast journal</td><td>Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasib...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18796377/" target="_blank">18796377</a></td><td>2008</td><td>Article</td><td>Clinical &amp; translational oncol</td><td>Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38304030/" target="_blank">38304030</a></td><td>2023</td><td>Article</td><td>Frontiers in oncology</td><td>Case report: Urothelial injury in a female with breast cancer: a rare adverse ev...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35985745/" target="_blank">35985745</a></td><td>2022</td><td>Article</td><td>BMJ case reports</td><td>First report of bilateral synchronous male accessory breast cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39401811/" target="_blank">39401811</a></td><td>2024</td><td>Article</td><td>Zhongguo zhen jiu = Chinese ac</td><td>[Electroacupuncture with different frequencies for paclitaxel-induced peripheral...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35022341/" target="_blank">35022341</a></td><td>2022</td><td>Article</td><td>Internal medicine (Tokyo, Japa</td><td>Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment fo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24423958/" target="_blank">24423958</a></td><td>2014</td><td>Article</td><td>Gan to kagaku ryoho. Cancer &amp; </td><td>[A case of carcinomatous cardiac tamponade caused by breast cancer treated with ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15550852/" target="_blank">15550852</a></td><td>2004</td><td>Article</td><td>Breast cancer (Tokyo, Japan)</td><td>Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26869049/" target="_blank">26869049</a></td><td>2016</td><td>Article</td><td>The Lancet. Oncology</td><td>Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for e...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27668497/" target="_blank">27668497</a></td><td>2016</td><td>Article</td><td>Optometry and vision science :</td><td>Bilateral Corneal Epithelial Lesions Associated with Paclitaxel.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8649555/" target="_blank">8649555</a></td><td>1996</td><td>Article</td><td>Neurology</td><td>Transient encephalopathy after paclitaxel (Taxol) infusion.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. breast carcinoma by gene expression profile</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（45 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02628132" target="_blank">NCT02628132</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>22</td><td>Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00589238" target="_blank">NCT00589238</a></td><td>PHASE2</td><td>TERMINATED</td><td>16</td><td>Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Comp...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03725436" target="_blank">NCT03725436</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>35</td><td>A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01722968" target="_blank">NCT01722968</a></td><td>PHASE2</td><td>COMPLETED</td><td>33</td><td>A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Me...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00499291" target="_blank">NCT00499291</a></td><td>NA</td><td>WITHDRAWN</td><td>0</td><td>Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Na...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02645175" target="_blank">NCT02645175</a></td><td>PHASE2</td><td>TERMINATED</td><td>3</td><td>A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the S...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04939610" target="_blank">NCT04939610</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>222</td><td>LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investiga...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02685059" target="_blank">NCT02685059</a></td><td>PHASE2</td><td>COMPLETED</td><td>174</td><td>A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI47...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06371807" target="_blank">NCT06371807</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>20</td><td>Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05503108" target="_blank">NCT05503108</a></td><td>PHASE3</td><td>SUSPENDED</td><td>10</td><td>DIRECT-2: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in HR+, HER2- B...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00038402" target="_blank">NCT00038402</a></td><td>PHASE3</td><td>COMPLETED</td><td>74</td><td>Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuv...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00070278" target="_blank">NCT00070278</a></td><td>PHASE3</td><td>UNKNOWN</td><td>800</td><td>A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphami...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00088829" target="_blank">NCT00088829</a></td><td>PHASE2</td><td>TERMINATED</td><td>22</td><td>A Pilot Study to Establish a Standardized Protocol for Gene Microarray Analysis ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05582499" target="_blank">NCT05582499</a></td><td>PHASE2</td><td>RECRUITING</td><td>716</td><td>Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05749575" target="_blank">NCT05749575</a></td><td>PHASE2</td><td>UNKNOWN</td><td>28</td><td>A Prospective, Open-label, Phase II Clinical Trial of Chidamide, PD-1 Monoclonal...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01763710" target="_blank">NCT01763710</a></td><td>PHASE2</td><td>COMPLETED</td><td>60</td><td>Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05912062" target="_blank">NCT05912062</a></td><td>N/A</td><td>UNKNOWN</td><td>80</td><td>Early On-treatment Transcriptional Profiling as Predictor of Response in Early-s...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05831553" target="_blank">NCT05831553</a></td><td>N/A</td><td>UNKNOWN</td><td>100</td><td>Evaluation of a Tissue Immune Profile (TIP) in Patients Affected by Metastatic T...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02069158" target="_blank">NCT02069158</a></td><td>PHASE1</td><td>COMPLETED</td><td>17</td><td>DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WI...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01367288" target="_blank">NCT01367288</a></td><td>PHASE2</td><td>COMPLETED</td><td>53</td><td>Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Manage...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00537173" target="_blank">NCT00537173</a></td><td>N/A</td><td>TERMINATED</td><td>11</td><td>Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin fo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01973660" target="_blank">NCT01973660</a></td><td>PHASE2</td><td>COMPLETED</td><td>151</td><td>PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadj...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01750073" target="_blank">NCT01750073</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>92</td><td>A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Pat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00991263" target="_blank">NCT00991263</a></td><td>N/A</td><td>COMPLETED</td><td>3677</td><td>Intrinsic Breast Cancer Subtypes and Benefit of Paclitaxel in CALGB 9344 and Dos...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00820690" target="_blank">NCT00820690</a></td><td>N/A</td><td>UNKNOWN</td><td>80</td><td>Gene Expression Signature and Immunohistochemical Markers Associated With Respon...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06561607" target="_blank">NCT06561607</a></td><td>PHASE3</td><td>NOT_YET_RECRUITING</td><td>542</td><td>A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00717340" target="_blank">NCT00717340</a></td><td>PHASE1</td><td>COMPLETED</td><td>18</td><td>A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combinati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03168880" target="_blank">NCT03168880</a></td><td>PHASE3</td><td>ACTIVE_NOT_RECRUITING</td><td>720</td><td>A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Pac...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02938442" target="_blank">NCT02938442</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>16</td><td>A Combined Phase i/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00486668" target="_blank">NCT00486668</a></td><td>PHASE3</td><td>UNKNOWN</td><td>529</td><td>A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable a...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04248998" target="_blank">NCT04248998</a></td><td>PHASE2</td><td>UNKNOWN</td><td>30</td><td>Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoth...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00899509" target="_blank">NCT00899509</a></td><td>N/A</td><td>COMPLETED</td><td>1500</td><td>Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Proto...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05233696" target="_blank">NCT05233696</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherap...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05422794" target="_blank">NCT05422794</a></td><td>PHASE1</td><td>RECRUITING</td><td>57</td><td>A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel i...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00436566" target="_blank">NCT00436566</a></td><td>PHASE2</td><td>COMPLETED</td><td>122</td><td>Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01501487" target="_blank">NCT01501487</a></td><td>PHASE4</td><td>COMPLETED</td><td>226</td><td>MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01617668" target="_blank">NCT01617668</a></td><td>PHASE2</td><td>COMPLETED</td><td>209</td><td>A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Pac...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01802970" target="_blank">NCT01802970</a></td><td>PHASE1</td><td>COMPLETED</td><td>10</td><td>Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00499083" target="_blank">NCT00499083</a></td><td>PHASE2</td><td>COMPLETED</td><td>17</td><td>Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01796197" target="_blank">NCT01796197</a></td><td>PHASE2</td><td>COMPLETED</td><td>23</td><td>Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Ope...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00336791" target="_blank">NCT00336791</a></td><td>PHASE3</td><td>COMPLETED</td><td>273</td><td>Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expressi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00898690" target="_blank">NCT00898690</a></td><td>N/A</td><td>UNKNOWN</td><td>120</td><td>Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03058939" target="_blank">NCT03058939</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigeria...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03283384" target="_blank">NCT03283384</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>100</td><td>Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Lumin...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00503906" target="_blank">NCT00503906</a></td><td>PHASE2</td><td>COMPLETED</td><td>30</td><td>A Phase II Study of Abraxane, Avastin and Gemcitabine for First Line Metastatic ...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26372358/" target="_blank">26372358</a></td><td>2016</td><td>Article</td><td>Molecular oncology</td><td>Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer de...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39400682/" target="_blank">39400682</a></td><td>2024</td><td>Article</td><td>Medical oncology (Northwood, L</td><td>Glycolytic pathway analysis and gene expression profiles of combination of aloe ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30426838/" target="_blank">30426838</a></td><td>2018</td><td>Article</td><td>Molecular pain</td><td>Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36602784/" target="_blank">36602784</a></td><td>2023</td><td>Article</td><td>JAMA oncology</td><td>Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27094684/" target="_blank">27094684</a></td><td>2016</td><td>Article</td><td>Scientific reports</td><td>Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25000515/" target="_blank">25000515</a></td><td>2014</td><td>Article</td><td>Pharmacogenetics and genomics</td><td>Gene expression of peripheral blood cells reveals pathways downstream of glucoco...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39375938/" target="_blank">39375938</a></td><td>2024</td><td>Article</td><td>Cancer science</td><td>Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy tr...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37148401/" target="_blank">37148401</a></td><td>2023</td><td>Article</td><td>Naunyn-Schmiedeberg&#x27;s archives</td><td>Exploring the mechanism by which quercetin re-sensitizes breast cancer to paclit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38999963/" target="_blank">38999963</a></td><td>2024</td><td>Article</td><td>International journal of molec</td><td>Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35875026/" target="_blank">35875026</a></td><td>2022</td><td>Article</td><td>Frontiers in public health</td><td>Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39741209/" target="_blank">39741209</a></td><td>2024</td><td>Article</td><td>Cellular and molecular life sc</td><td>Microtubule acetylation and PERK activation facilitate eribulin-induced mitochon...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34131286/" target="_blank">34131286</a></td><td>2021</td><td>Article</td><td>Oncogene</td><td>Individualized lncRNA differential expression profile reveals heterogeneity of b...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27420999/" target="_blank">27420999</a></td><td>2016</td><td>Article</td><td>Genetics and molecular researc</td><td>Molecular-level effects of eribulin and paclitaxel on breast cancer based on dif...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30999914/" target="_blank">30999914</a></td><td>2019</td><td>Article</td><td>Molecular cancer</td><td>Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39308141/" target="_blank">39308141</a></td><td>2024</td><td>Article</td><td>Clinical cancer research : an </td><td>The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40615664/" target="_blank">40615664</a></td><td>2025</td><td>Article</td><td>Scientific reports</td><td>Machine learning combined with multi-omics to identify immune-related LncRNA sig...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40350044/" target="_blank">40350044</a></td><td>2025</td><td>Article</td><td>Biochimica et biophysica acta.</td><td>Characterization and targeting of chemoresistant triple-negative breast cancer s...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38837893/" target="_blank">38837893</a></td><td>2024</td><td>Article</td><td>Clinical cancer research : an </td><td>Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23923010/" target="_blank">23923010</a></td><td>2013</td><td>Article</td><td>PloS one</td><td>Prognostic significance of ESR1 gene amplification, mRNA/protein expression and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28835684/" target="_blank">28835684</a></td><td>2017</td><td>Article</td><td>Scientific reports</td><td>Modulation of SOX2 expression delineates an end-point for paclitaxel-effectivene...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. nipple carcinoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03875573" target="_blank">NCT03875573</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>147</td><td>Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Pr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00616967" target="_blank">NCT00616967</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>68</td><td>A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrog...</td></tr>
</tbody>
</table>

<h3>相關文獻（10 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39233823/" target="_blank">39233823</a></td><td>2024</td><td>Article</td><td>Oncology letters</td><td>Neoadjuvant chemotherapy for primary invasive ductal carcinoma of the nipple: A ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33827325/" target="_blank">33827325</a></td><td>2021</td><td>Article</td><td>International journal of surgi</td><td>Acinic Cell Carcinoma of the Breast: Report of a Case With Immunohistochemical a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37064212/" target="_blank">37064212</a></td><td>2023</td><td>Article</td><td>Case reports in women&#x27;s health</td><td>Ovarian high-grade serous carcinoma with estrogenic manifestations in a postmeno...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29514832/" target="_blank">29514832</a></td><td>2018</td><td>Article</td><td>BMJ case reports</td><td>Rare case of metaplastic breast cancer in a man.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38741768/" target="_blank">38741768</a></td><td>2024</td><td>Article</td><td>Frontiers in medicine</td><td>Untypical bilateral breast cancer with peritoneal fibrosis on 18F-FDG PET/CT: ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28133220/" target="_blank">28133220</a></td><td>2016</td><td>Article</td><td>Gan to kagaku ryoho. Cancer &amp; </td><td>[A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39682607/" target="_blank">39682607</a></td><td>2024</td><td>Article</td><td>Diagnostics (Basel, Switzerlan</td><td>Synchronous Primary Metastatic Infra-Mammary Accessory Breast Cancer and Ipsilat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22083199/" target="_blank">22083199</a></td><td>2011</td><td>Article</td><td>Gan to kagaku ryoho. Cancer &amp; </td><td>[A case of pagetoid carcinoma of the breast in nearly complete response by prima...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14981568/" target="_blank">14981568</a></td><td>2004</td><td>Article</td><td>Zentralblatt fur Gynakologie</td><td>[Primary intracystic squamous cell cancer of female breast].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33468796/" target="_blank">33468796</a></td><td>2020</td><td>Article</td><td>Gan to kagaku ryoho. Cancer &amp; </td><td>[Treatment Regimens for Breast Cancer in Elderly Patients in Whom the Diagnosis ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. parameningeal embryonal rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. botryoid-type embryonal rhabdomyosarcoma of the vagina</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.73%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

Paclitaxel 在台灣有多種製劑核准上市，包括：

- 傳統溶劑型 Paclitaxel 注射劑
- Nab-paclitaxel (白蛋白結合型)
- Paclitaxel 微脂粒注射劑

原適應症已涵蓋乳癌的多種類型。

---

## 安全性考量

### 重要警語

- **過敏反應**：傳統製劑含 Cremophor EL，可能導致嚴重過敏反應，需預防給藥
- **骨髓抑制**：嗜中性球低下為劑量限制毒性
- **周邊神經病變**：累積劑量相關，可能不可逆
- **心臟毒性**：與 anthracycline 併用時需注意

### 常見副作用

| 副作用 | 發生率 |
|--------|--------|
| 骨髓抑制 | 非常常見 |
| 周邊神經病變 | 常見 |
| 肌肉關節痛 | 常見 |
| 噁心嘔吐 | 常見 |
| 掉髮 | 非常常見 |

### 藥物交互作用

- **CYP3A4 及 CYP2C8 抑制劑**：可能增加 paclitaxel 血中濃度
- **CYP3A4 誘導劑**：可能降低療效
- **Anthracyclines**：建議先給 paclitaxel 再給 anthracycline

### 特殊族群

- **肝功能不全**：需根據膽紅素及 AST 調整劑量
- **孕婦**：禁忌使用
- **老年人**：周邊神經病變風險較高

---




### 藥物-食物交互作用 (DFI)

<div class="dfi-source">資料來源：<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>（原文內容請參閱該網站）</div>

**葡萄柚汁** 🟡 Moderate
- 影響：影響藥物代謝。可能增加藥物血中濃度。
- 建議：需監測療效或不良反應。可能需調整劑量。避免食用葡萄柚或葡萄柚汁。

### 藥物-草藥交互作用 (DHI)

**聖約翰草（貫葉連翹）** 🔴 Major
- 影響：聖約翰草降低化療藥物療效
- 建議：化療期間禁用所有草藥補充品


## 結論與下一步

### 整體評估

Paclitaxel 對乳癌的預測已獲得最高等級的臨床證據支持：

1. **證據等級最高 (L1)**：多個 Phase III 臨床試驗證實療效
2. **機轉清晰**：微管穩定及免疫調節雙重作用
3. **臨床應用成熟**：已是乳癌標準治療的重要組成部分
4. **持續創新**：與免疫療法併用的新組合正在研究中

### 目前臨床定位

| 乳癌亞型 | Paclitaxel 在治療中的角色 |
|----------|---------------------------|
| 三陰性乳癌 | 第一線化療核心藥物，常與免疫療法併用 |
| HER2+ 乳癌 | 與 trastuzumab 併用的標準方案 |
| ER+/HER2- 乳癌 | 荷爾蒙治療無效後的化療選項 |
| 發炎性乳癌 | 前導化療的重要成分 |

### 建議行動

- **持續作為標準治療**：Paclitaxel 在乳癌治療中的地位已確立
- **關注新組合療法**：與 PD-1/PD-L1 抑制劑的併用研究
- **個人化醫療**：根據生物標記選擇最適合的治療組合

---

*本報告由 TxGNN 預測系統生成，僅供研究參考，不構成醫療建議。*


---

## 相關藥物報告

- [Benzylpenicillin]({{ "/drugs/benzylpenicillin/" | relative_url }}) - 證據等級 L5
- [Allopurinol]({{ "/drugs/allopurinol/" | relative_url }}) - 證據等級 L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - 證據等級 L5
- [Thiamine]({{ "/drugs/thiamine/" | relative_url }}) - 證據等級 L5
- [Buprenorphine]({{ "/drugs/buprenorphine/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Paclitaxel老藥新用驗證報告. https://twtxgnn.yao.care/drugs/paclitaxel/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_paclitaxel,
  title = {Paclitaxel老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/paclitaxel/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
